Cargando…
Immunotherapy for pancreatic cancer
Pancreatic cancer, a highly lethal cancer, has the lowest 5-year survival rate for several reasons, including its tendency for the late diagnosis, a lack of serologic markers for screening, aggressive local invasion, its early metastatic dissemination, and its resistance to chemotherapy/radiotherapy...
Autores principales: | Yoon, Jai Hoon, Jung, Ye-Ji, Moon, Sung-Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080736/ https://www.ncbi.nlm.nih.gov/pubmed/33969083 http://dx.doi.org/10.12998/wjcc.v9.i13.2969 |
Ejemplares similares
-
Proton pump inhibitor: The dual role in gastric cancer
por: Joo, Moon Kyung, et al.
Publicado: (2019) -
Sarcopenia in pancreatic cancer: Effect on patient outcomes
por: Choi, Moon Hyung, et al.
Publicado: (2022) -
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
por: Guo, Songchuan, et al.
Publicado: (2017) -
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
por: Sarantis, Panagiotis, et al.
Publicado: (2020) -
Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer
por: Ko, Sung Woo, et al.
Publicado: (2023)